Technology firm, Pestra Ltd, has expressed its readiness to advance technology development in Nigeria.
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback